Abstract
Type 2 diabetes mellitus (T2DM) is a serious health problem with epidemic proportions and associated with high cardiovascular morbidity and mortality. Thus, the prevention or at least delaying the onset of T2DM is imperative. Subjects with impaired glucose metabolism (prediabetes) are highly likely to develop overt T2DM. Treatment of accompanied cardiovascular risk factors, such as hypertension and dyslipidemia, in these patients is frequently complicated as it can impair the already altered glucose homeostasis. This review discusses the pathophysiology of lipid disorders and hypertension in prediabetes along with the effects of lipid modifying and antihypertensive drugs in glucose/insulin metabolism. A critical overview and suggestions of different treatment options for prediabetic patients with dyslipidemia and/or hypertension are also presented.
Keywords: Aldosterone, angiotensin, dyslipidemia, fibrates, hypertension, new-onset diabetes, prediabetes, statins.
Current Pharmaceutical Design
Title:How Should We Treat Hypertension and Dyslipidemia in Patients with Prediabetes?
Volume: 19 Issue: 21
Author(s): Vasilios Tsimihodimos, Matilda Florentin and Moses S. Elisaf
Affiliation:
Keywords: Aldosterone, angiotensin, dyslipidemia, fibrates, hypertension, new-onset diabetes, prediabetes, statins.
Abstract: Type 2 diabetes mellitus (T2DM) is a serious health problem with epidemic proportions and associated with high cardiovascular morbidity and mortality. Thus, the prevention or at least delaying the onset of T2DM is imperative. Subjects with impaired glucose metabolism (prediabetes) are highly likely to develop overt T2DM. Treatment of accompanied cardiovascular risk factors, such as hypertension and dyslipidemia, in these patients is frequently complicated as it can impair the already altered glucose homeostasis. This review discusses the pathophysiology of lipid disorders and hypertension in prediabetes along with the effects of lipid modifying and antihypertensive drugs in glucose/insulin metabolism. A critical overview and suggestions of different treatment options for prediabetic patients with dyslipidemia and/or hypertension are also presented.
Export Options
About this article
Cite this article as:
Tsimihodimos Vasilios, Florentin Matilda and S. Elisaf Moses, How Should We Treat Hypertension and Dyslipidemia in Patients with Prediabetes?, Current Pharmaceutical Design 2013; 19 (21) . https://dx.doi.org/ 10.2174/13816128113199990304
DOI https://dx.doi.org/ 10.2174/13816128113199990304 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
VIP in Neurological Diseases: More Than A Neuropeptide
Endocrine, Metabolic & Immune Disorders - Drug Targets Impaired Cerebral Autoregulation and Vasomotor Reactivity in Sporadic Alzheimer’s Disease
Current Alzheimer Research Editorial [Hot Topic: The Medicinal Chemistry of New Agents to Treat Obesity (Guest Editor: Jinhwa Lee)]
Current Topics in Medicinal Chemistry A Review of Obesity and Body Fat Distribution and Its Relationship to Cardio-Metabolic Risk in Men and Women of Chinese Origin
Cardiovascular & Hematological Disorders-Drug Targets Cardiovascular Risk Factors: Does Sex Matter?
Current Vascular Pharmacology Structural Features of Angiotensin-I Converting Enzyme Catalytic Sites: Conformational Studies in Solution, Homology Models and Comparison with Other Zinc Metallopeptidases
Current Topics in Medicinal Chemistry Endothelial Dysfunction and Platelet Hyperaggregation in Type 2 Diabetes Mellitus: The Era of Novel Anti-diabetic Agents
Current Medicinal Chemistry Efficacy of the Newest COX-2 Selective Inhibitors in Rheumatic Disease
Current Pharmaceutical Design Diabetes Mellitus: Novel Insights, Analysis and Interpretation of Pathophysiology and Complications Management with Imidazole-Containing Peptidomimetic Antioxidants
Recent Patents on Drug Delivery & Formulation Models to Study Atherosclerosis: A Mechanistic Insight
Current Vascular Pharmacology Approaches for the Development of Drugs for Treatment of Obesity and Metabolic Syndrome
Current Pharmaceutical Design Hydralazine-Induced ANCA Associated Vasculitis (AAV) Presenting with Pulmonary-Renal Syndrome (PRS): A Case Report with Literature Review
Current Cardiology Reviews Safety of Dabigatran in an Elderly Population: Single Center Experience in Italy
Current Drug Safety Open Questions about Pulmonary Hypertension and Exercise Training: A Critical Review
Current Respiratory Medicine Reviews Is Nonalcoholic Fatty Liver Disease Indeed the Hepatic Manifestation of Metabolic Syndrome?
Current Vascular Pharmacology Development of Radiolabeled Compounds for Myocardial Perfusion Imaging
Current Pharmaceutical Design Novel Neuroendocrine and Metabolic Mechanism Provides the Patented Platform for Important Rejuvenation Therapies: Targeted Therapy of Telomere Attrition and Lifestyle Changes of Telomerase Activity with the Timing of Neuron-Specific Imidazole-Containing Dipeptide-Dominant Pharmaconutrition Provision
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery Current Status of Rho-Associated Kinases (ROCKs) in Coronary Atherosclerosis and Vasospasm
Cardiovascular & Hematological Agents in Medicinal Chemistry Vitamin D Supplementation: A Promising Approach for the Prevention and Treatment of Strokes
Current Drug Targets An Efficient and Eco-Friendly Procedure for the Synthesis of Hantzsch Ethyl 1,4-Dihydro-2,6-Dimethylpyridine-3,5-Dicarboxylates Under Mild and Green Conditions
Letters in Organic Chemistry